JP2024527629A - 治療用ムテイン - Google Patents
治療用ムテイン Download PDFInfo
- Publication number
- JP2024527629A JP2024527629A JP2024503765A JP2024503765A JP2024527629A JP 2024527629 A JP2024527629 A JP 2024527629A JP 2024503765 A JP2024503765 A JP 2024503765A JP 2024503765 A JP2024503765 A JP 2024503765A JP 2024527629 A JP2024527629 A JP 2024527629A
- Authority
- JP
- Japan
- Prior art keywords
- mutein
- seq
- cytokine
- amino acid
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2110547.3A GB202110547D0 (en) | 2021-07-22 | 2021-07-22 | Therapeutic muteins |
| GB2110547.3 | 2021-07-22 | ||
| FR2203600 | 2022-04-19 | ||
| FR2203600 | 2022-04-19 | ||
| PCT/EP2022/070548 WO2023001987A2 (en) | 2021-07-22 | 2022-07-21 | Therapeutic muteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527629A true JP2024527629A (ja) | 2024-07-25 |
| JP2024527629A5 JP2024527629A5 (https=) | 2025-07-28 |
Family
ID=82942857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503765A Pending JP2024527629A (ja) | 2021-07-22 | 2022-07-21 | 治療用ムテイン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240352084A1 (https=) |
| EP (1) | EP4373848A2 (https=) |
| JP (1) | JP2024527629A (https=) |
| CA (1) | CA3226397A1 (https=) |
| IL (1) | IL310292A (https=) |
| WO (1) | WO2023001987A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023249425A1 (ko) * | 2022-06-22 | 2023-12-28 | ㈜지아이이노베이션 | 항-cd73 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
| AU2024330564A1 (en) | 2023-08-30 | 2026-04-02 | Xilio Development, Inc. | Vhh masked cytokines and methods of use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7569215B2 (en) * | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CA3007135A1 (en) | 2016-03-23 | 2017-09-28 | Mabspace Biosciences (Suzhou) Co., Ltd | Novel anti-pd-l1 antibodies |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| WO2018045110A1 (en) | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| PE20250933A1 (es) | 2017-03-14 | 2025-04-02 | Five Prime Therapeutics Inc | Anticuerpos de union a vista a ph acido |
| US20180339043A1 (en) | 2017-05-26 | 2018-11-29 | Janux Therapeutics, Inc. | Modified antibodies |
| US12202911B2 (en) | 2017-10-10 | 2025-01-21 | Numab Therapeutics AG | Multispecific antibody comprising CD137 binding domain and PDL1 binding domain |
| IL275426B2 (en) * | 2017-12-19 | 2025-03-01 | Xencor Inc | Engineered il-2 fc fusion proteins |
| WO2019152413A1 (en) | 2018-02-02 | 2019-08-08 | Oncoimmune, Inc. | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy |
| BR112020019083A2 (pt) | 2018-03-21 | 2020-12-29 | Five Prime Therapeutics, Inc. | Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer |
| US10597453B2 (en) | 2018-06-29 | 2020-03-24 | Gensun Biopharma, Inc. | Antitumor immune checkpoint regulator antagonists |
| US20220002370A1 (en) | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| CN119874917A (zh) | 2019-06-07 | 2025-04-25 | 阿迪马布有限责任公司 | 工程化的pH依赖性抗CD3抗体及其产生和使用方法 |
| KR102560876B1 (ko) | 2019-06-11 | 2023-07-28 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 항-epcam 항체, 항체 단편, 이들의 면역접합체 및 이의 용도 |
| PH12022550326A1 (en) | 2019-08-13 | 2023-03-13 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
-
2022
- 2022-07-21 EP EP22757224.5A patent/EP4373848A2/en active Pending
- 2022-07-21 WO PCT/EP2022/070548 patent/WO2023001987A2/en not_active Ceased
- 2022-07-21 CA CA3226397A patent/CA3226397A1/en active Pending
- 2022-07-21 US US18/290,928 patent/US20240352084A1/en active Pending
- 2022-07-21 JP JP2024503765A patent/JP2024527629A/ja active Pending
- 2022-07-21 IL IL310292A patent/IL310292A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3226397A1 (en) | 2023-01-26 |
| WO2023001987A3 (en) | 2023-03-16 |
| EP4373848A2 (en) | 2024-05-29 |
| US20240352084A1 (en) | 2024-10-24 |
| IL310292A (en) | 2024-03-01 |
| WO2023001987A2 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7447232B2 (ja) | アルブミン結合ドメイン融合タンパク質 | |
| JP7142630B2 (ja) | ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ－融合タンパク質 | |
| KR102609197B1 (ko) | 인터류킨 15 단백질 복합체 및 그의 용도 | |
| US20240181009A1 (en) | Synthekine compositions and methods of use | |
| CN112055717B (zh) | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 | |
| JP2020073537A (ja) | 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体 | |
| MX2012013899A (es) | Proteinas de fusion vstm3 dimericas y composiciones y metodos relacionados. | |
| KR20210021467A (ko) | 활성화가능한 인터루킨-2 폴리펩타이드 및 이의 사용 방법 | |
| JP2024527629A (ja) | 治療用ムテイン | |
| CN116322785A (zh) | 包含il-10的双细胞因子融合蛋白 | |
| CN115515970A (zh) | Il-10突变蛋白 | |
| KR20240159831A (ko) | 인터류킨을 이용하여 이중특이적 t 세포 인게이저 또는 키메라 항원 수용체 t 세포 매개 시토카인 방출 증후군을 감소시키는 방법 | |
| Bick et al. | Targeting γc family cytokines with biologics: current status and future prospects | |
| EP4171609A1 (en) | Cytokine conjugates | |
| Krautwald et al. | Ectopic expression of CCL19 impairs alloimmune response in mice | |
| CN117999280A (zh) | 治疗性突变蛋白 | |
| JP2023521174A (ja) | インターロイキン１受容体アクセサリータンパク質に特異的なバインダーおよびキメラ抗原受容体 | |
| US20250236653A1 (en) | Targeted low potency il-12 fc fusion proteins and uses thereof | |
| US20250288666A1 (en) | Methods and compositions for use in cell therapy of neoplastic disease | |
| Fisher | Improving CAR-T Cell Proliferation and Efficacy Using Cytokine Stimulation and Novel Fusion Protein Selection | |
| RU2786444C2 (ru) | Слитые белки с альбумин-связывающими доменами | |
| Nguyen | Effect of Heparin on the Immunobiology of Interleukin 12 | |
| WO2024238287A1 (en) | Dual blocking and chimeric cytokine receptor | |
| KR20260032470A (ko) | Hpv 백신 요법의 결과로 생성된 t 세포 수용체 및 이를 이용하여 환자를 치료하는 방법 | |
| JP2025535705A (ja) | インターロイキン２１模倣体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250716 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250716 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20260220 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20260226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20260220 |